Up to 50,000 New Zealanders per year will benefit from a new multiproduct agreement PHARMAC has reached with Novartis, which makes more funded medicines available for a wide range of health conditions.
PHARMAC is celebrating the formation of New Zealand’s first Pacific Pharmacists’ Association. PHARMAC Chief Executive, Sarah Fitt, says PHARMAC is proud to support Pacific pharmacists working...
PHARMAC and Te Pōari o Te Rūnanga o Āotearoa and their Tiriti partner Tōpūtanga Tapuhi Kaitiaki o Āotearoa (NZNO) are pleased to announce the inaugural recipients of the Tapuhi Katiaki Awards.
If you get a cold or flu this winter, taking antibiotics won’t fix it.
PHARMAC is progressing work aimed at improving funded access to medicines for rare disorders.
PHARMAC is pleased to provide another treatment option for patients with severe osteoporosis following the funding of denosumab, brand name Prolia, from 1 July 2018.
PHARMAC and Te Pōari o Te Rūnanga o Aotearoa/ Tōpūtanga Tapuhi Kaitiaki o Aotearoa/New Zealand Nursing Organisation (NZNO) are pleased to announce the launch of the Tapuhi Kaitiaki Awards (Māori Nurses Awards).
This year, PHARMAC is reviewing the way we seek and incorporate the consumer voice in our work, and is asking people about how we could improve input from, or engagement with, them.
PHARMAC is pleased that the Government has announced an uplift in PHARMAC’s funding.
Thousands of New Zealanders will benefit from advances in treatment as a result of two PHARMAC funding decisions. The first decision is to fund a medication for treating a degenerative eye condition, and the second is to fund another oral anticoagulant option for the prevention of strokes and the prevention or treatment of blood clots.
PHARMAC and Ngā Kaitiaki o Te Puna Rongoā ō Āotearoa (Māori Pharmacists Association) recently celebrated the 10th year of the Hiwinui Heke, Māori Pharmacy Student Scholarships in Rotorua.
The influenza vaccine used in New Zealand this year will include protection against infection with four strains of the virus.
A decision to widen access to Truvada to prevent infection with HIV is a great opportunity to reduce transmission rates of HIV infections in New Zealand, says PHARMAC Chief Executive Sarah Fitt.
PHARMAC is supporting New Zealand’s first Pacific pharmacists' group to establish itself as a formal entity.
Funding cetuximab for patients with head and neck cancer will be a significant advance for treating this type of cancer in New Zealand, says PHARMAC Director of Operations Sarah Fitt.
Post-menopausal women with early breast cancer will soon be able to have funded zoledronic acid, to prevent the disease spreading into bones.
Achieving equity in medicines access is one of the bold goals PHARMAC has set itself to achieve by 2025.
PHARMAC is welcoming the presentation of results from the international SOLD trial, comparing short and long duration treatment with trastuzumab (Herceptin) for early HER 2-positive breast cancer.
PHARMAC is giving people a choice of four funded CareSens meters, including a dual meter that measures both blood glucose and ketones.
Stuart McLauchlan Chair PHARMAC today announced that Sarah Fitt, Director of Operations will be appointed as PHARMAC's new Chief Executive effective from Saturday 6 January 2018